Perrigo Ends 2017 As It Started: Earnings Results Delayed
Executive Summary
You may also be interested in...
Perrigo Finding Balance As Three-Legged Stool With Two Consumer Units, Rx Division
As new CEO Uwe Röhrhoff plans a "value creation" analysis, the improving Rx business growth could be essential for company because US competition from smaller, online brands is increasing in the OTC drug space and its sales of its consumer health products in Europe have yet to reach expectations.
Perrigo Finding Balance As Three-Legged Stool With Two Consumer Units, Rx Division
As new CEO Uwe Röhrhoff plans a "value creation" analysis, the improving Rx business growth could be essential for company because US competition from smaller, online brands is increasing in the OTC drug space and its sales of its consumer health products in Europe have yet to reach expectations.
Outgoing CEO: Perrigo Outfitted To Sail On OTC, Rx And Euro Growth
Hendrickson recounts Perrigo's strategies to right the ship after a hole in earnings opened from investing in a European consumer health business and operating API and dietary supplement divisions and as pricing pressures on generic drugs took some wind out of its revenue sails.